Analysts at Stifel Nicolaus initiated coverage on shares of Kura Oncology (NASDAQ:KURA – Get Rating) in a research report issued to clients and investors on Monday, The Fly reports. The firm set a "buy" rating on the stock.

Separately, StockNews.com initiated coverage on Kura Oncology in a research note on Wednesday, October 12th. They set a "sell" rating on the stock. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $32.40.

Kura Oncology Stock Down 3.7 %

NASDAQ KURA traded down $0.50 during trading hours on Monday, hitting $13.14. 364,475 shares of the company were exchanged, compared to its average volume of 760,657. The stock has a 50-day moving average price of $13.58 and a 200 day moving average price of $14.51. Kura Oncology has a 52 week low of $10.41 and a 52 week high of $19.93. The stock has a market cap of $879.07 million, a PE ratio of -6.47 and a beta of 0.90.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Great West Life Assurance Co. Can purchased a new position in shares of Kura Oncology during the third quarter valued at approximately $39,000. Nisa Investment Advisors LLC boosted its holdings in shares of Kura Oncology by 80.8% in the second quarter. Nisa Investment Advisors LLC now owns 3,290 shares of the company's stock valued at $60,000 after purchasing an additional 1,470 shares during the period. Amalgamated Bank purchased a new stake in shares of Kura Oncology in the first quarter valued at approximately $123,000. Annandale Capital LLC purchased a new stake in shares of Kura Oncology in the third quarter valued at approximately $137,000. Finally, Bridgefront Capital LLC purchased a new stake in shares of Kura Oncology in the first quarter valued at approximately $180,000.

Kura Oncology Company Profile

(Get Rating)

Kura Oncology, Inc operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias.

See Also

• Get a free copy of the StockNews.com research report on Kura Oncology (KURA)
• Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
• SoFi Technologies Smashes Earnings but Beware the Fed Decision
• Buying The Dip In Colgate-Palmolive
• Mullen Automotive On Hiring Spree, What Could That Mean?
• InterDigital Raises Its Earnings Guidance

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.